Diligence memo · auto-generated · as of July 2, 2026
Platinum Biosciences, Inc.
Platinum Biosciences, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Platinum Biosciences, Inc. operates in Biotech / Pharma, based in Plano.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Platinum Biosciences, Inc. has raised $750K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $500K on 2019-10-10.
Most recent recorded round closed around 2019-10-10.
Valuation (modeled)modeled
Provath models Platinum Biosciences, Inc. at approximately $26M (range $273K–$290M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 5.00× the median modeled value of Pre-Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 6.7 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 27% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: AbX Biologics, Inc., BC Green Pharmaceuticals Inc., Anubis Bio Corp., Green Star Biosciences Inc., Nexus Biologics, SPC.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.